Friday, 29 March, 2024
HomeHaematologyBlood thinners safe with brain metastases

Blood thinners safe with brain metastases

Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a new study.

Cancer increases a patient's risk of developing blood clots. When a patient with cancer develops a clot, treatment with a blood thinning medication is often added to their treatment regimen in order to prevent the potentially fatal complication of blood clots travelling to the lungs. However, if cancer spreads to the brain, anticoagulant treatment may be withheld because it could cause dangerous bleeding in the patient's head, which is already a risk for these patients.

The task of preventing dangerous blood clots and avoiding life-threatening bleeding presents a particular challenge for specialists in patients with tumour metastases in the brain. Until recently, no data had confirmed whether blood thinners could be safely administered in these patients.

In order to determine whether administering blood-thinning medication to patients with brain metastases and blood clots increases bleeding, researchers studied the medical records of 293 patients, 104 of whom had received a widely used blood thinner (enoxaparin). The remaining 189 patients did not receive blood-thinning treatment. Researchers matched the patients in each group by year of brain metastases diagnosis, tumour type, age, and gender.

Based on their reviews of patients' medical records, researchers determined that there was no significant difference in the risk of bleeding between the patients who received enoxaparin and those who did not after 12 months. Cumulative incidence of bleeding in the head was 44% in the enoxaparin group versus 37% in the group that did not receive treatment. Regardless of treatment with enoxaparin, investigators observed a high bleeding rate among all patients with brain metastases (between 20-50%), consistent with the notion that bleeding is more common than originally thought.

"While it is a very common clinical scenario to treat a patient with a metastatic brain tumour who also develops a blood clot, before this study there was very little data to inform the difficult decision of whether or not to anticoagulate these patients," said senior study author Dr Jeffrey Zwicker, of Beth Israel Deaconess Medical Centre and Harvard Medical School. "Our findings, which demonstrate that current practice is safe, should reassure physicians that anticoagulants can be safely administered to patients with brain metastases and a history of blood clots."

[link url="http://www.eurekalert.org/pub_releases/2015-05/asoh-sbt051815.php"]American Society of Hematology material[/link]
[link url="http://www.bloodjournal.org/content/early/2015/05/18/blood-2015-02-626788"]Blood abstract[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.